Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker UPTD, filed an 8-K with the SEC on February 21, 2023, marking a current-report disclosure tied to the company's SPAC-backed entry into the public markets. Operating in the biopharmaceutical sector with a focus on immunotherapy, Estrella Immunopharma emerged through a SPAC business combination that brought the clinical-stage company onto Nasdaq. The February 2023 filing reflects activity during the post-merger integration period as the company established its public reporting cadence. Investors tracking SPAC-derived biotech names can find the full filing history, deal timeline, and structured data for UPTD on SpacDesk — sign up at SpacDesk.com for complete access.